Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventMay 5, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventMay 5, 2005View HTMLDownload DOCDownload PDFDownload XLS
PREC14APreliminary proxy statement containing contested solicitationsMay 4, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteMay 2, 2005View HTMLDownload DOCDownload PDFDownload XLS
PRE 14AA preliminary proxy statement providing notification matters to be brought to a voteMay 2, 2005View HTMLDownload DOCDownload PDFDownload XLS
10-K/AAmendment to a previously filed 10-KApr 29, 2005View HTMLDownload DOCDownload PDFDownload XLS
DFAN14AAdditional proxy soliciting materials filed by non-managementApr 22, 2005View HTMLDownload DOCDownload PDFDownload XLS
DFAN14AAdditional proxy soliciting materials filed by non-managementApr 18, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Apr 15, 2005View HTMLDownload DOCDownload PDFDownload XLS
PREC14APreliminary proxy statement containing contested solicitationsApr 15, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventApr 5, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GMar 31, 2005View HTMLDownload DOCDownload PDFDownload XLS
10-K/AAmendment to a previously filed 10-KMar 29, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventMar 29, 2005View HTMLDownload DOCDownload PDFDownload XLS
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 16, 2005View HTMLDownload DOCDownload PDFDownload XLS
NO ACTNo Action LettersMar 9, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventFeb 23, 2005View HTMLDownload DOCDownload PDFDownload XLS
SC 13G/AAmendment to a previously filed SC 13GFeb 14, 2005View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 14, 2005View HTMLDownload DOCDownload PDF
SC 13G/AAmendment to a previously filed SC 13GFeb 11, 2005View HTMLDownload DOCDownload PDF
5Annual filing director officer or owner of more than ten percent.Feb 11, 2005View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 10, 2005View HTMLDownload DOCDownload PDFDownload XLS
4Statement of changes in beneficial ownership of securitiesJan 31, 2005View HTMLDownload DOCDownload PDF
8-KReport of unscheduled material events or corporate eventJan 26, 2005View HTMLDownload DOCDownload PDFDownload XLS
8-KReport of unscheduled material events or corporate eventJan 12, 2005View HTMLDownload DOCDownload PDFDownload XLS
1-25      26-50      51-75      76-100      101-107

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Palynziq™
Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information